The global cost of diabetes is an unsustainable $1.25 trillion: 1.8% of global GDP. Spotlight Consultations’ evidence-based Spotlight-AQ aims to develop a new approach that helps reduce expenditure and healthcare burden whilst improving the quality of care & health outcomes through subscription-based clinic tools.
10% of global health expenditure p.a ($760bn) is spent on diabetes. This is predicted to rise to $825bn by 2030. Indirect costs from premature death, disability and diabetes-related health complications are estimated to add an additional 35% to this number. Intangible costs are less visible: worry, anxiety, discomfort, pain, loss of independence, fears for health.
Once it's fully developed Spotlight-AQ aims to be a simple 3-5 minute questionnaire, dynamically responsive with each question linked to an actionable care pathway. Easy-to-understand visual graphics show results and therapy options that are shared with healthcare professionals, facilitating shared decision-making to meet individual needs.
Once live, Spotlight-AQ will be charged at £1 per user. Our subscription model could provide an independent operating platform scalable to an entire national healthcare service e.g. individual clinics & doctors. We aim to produce digital health tools that are innovative; scale to different national and international health services, different languages and contain inbuilt audio/colour versions for people with low literacy. The investment will support early revenue generation, team expansion, R&D of tools in CVD, IBD, chronic pain and cancers.
Next steps: begin clinical trials in '21, launch to UK market followed by China & US with the guidance of an expert non-executive board.